ENGLEWOOD, Colo., Nov. 17,
2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc.
(NYSE American/OTC Pink: AMPE) (the "Company") received
notification from NYSE American LLC ("NYSE American" or the
"Exchange") stating that the staff of NYSE Regulation has withdrawn
its delisting determination and will be lifting the trading
suspension of the Company's common stock on the NYSE American.
Following the fifteen-to-one reverse stock split of the
Company's common stock, which became effective November 9, 2022, the NYSE Regulation staff
determined that the Company's common stock was trading above the
threshold of low selling price issues as further defined by Section
1003(f)(v) of the NYSE American Company Guide. As such, the
Exchange has withdrawn its delisting determination and will be
lifting the trading suspension of the Company's common stock on the
Ampio's continued listing on the Exchange will be predicated on
it demonstrating compliance with Section 1003(f)(v) of the NYSE
American Company Guide through a period of at least December 23, 2022. The Company will update
shareholders if and when it receives notification from the NYSE
American that it has achieved compliance on this matter.
Ampio's common stock will commence trading on the NYSE American
on Tuesday, November 22, 2022 under
the symbol "AMPE."
Caution Regarding Forward-Looking Statements
This press release includes certain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. All statements, other than statements of present or
historical fact, included in this document regarding the proposed
reverse stock split and strategic alternatives process are
forward-looking statements. These forward-looking statements are
subject to risks and uncertainties, including: the market price of
Ampio's common stock may not demonstrate sustained price
improvement to regain compliance with the NYSE American continued
listing standards during the cure period ending on December 23, 2022 or Ampio may not be able to
maintain listing on the NYSE American for any other reason.
Investor and Media Contacts:
Russo or Nic Johnson
View original content to download
SOURCE Ampio Pharmaceuticals, Inc.